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CLP-1, the mouse homologue of human Hexim1 protein, exerts inhibitory control on transcriptional
elongation factor-b of RNA transcript elongation. Previously, we have demonstrated that downreg-
ulation of cardiac lineage protein-1 (CLP-1) in CLP-1+/ heterozygous mice affords cardioprotection
against ischemia–reperfusion injury. Our current study results show that the improvement in car-
diac function in CLP-1+/ mice after ischemia–reperfusion injury is achieved through the potentia-
tion of redox signaling and their molecular targets including redox effector factor-1, nuclear
factor erythroid 2-related factor, and NADPH oxidase 4 and the active usage of thioredoxin-1, thio-
redoxin-2, glutaredoxin-1 and glutaredoxin-2. Our results suggest that drugs designed to down reg-
ulate CLP-1 could confer cardioprotection through the potentiation of redox cycling.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cardiac lineage protein-1, a mouse homologue of human
Hexim1 binds with and inhibits the positive transcription elonga-
tion factor-b (P-TEFb), which is composed of cyclin-dependent ki-
nase 9 (Cdk9) and cyclin T1 [1–3]. P-TEFb phosphorylates the
carboxyl-terminal domain (CTD) of RNA polymerase II, a major
substrate of P-TEFb, and upon phosphorylation elongates nascent
transcripts to form full-length messenger RNAs [2]. Hexim1
forms a protein–RNA complex composed of 7SK small nuclear
RNA and
P-TEFb, and inhibits the kinase activity of CDK9, leading to the
suppression of RNA polymerase II-dependent transcriptional
elongation [4]. Previously we have demonstrated that CLP-1
plays an essential role in the regulation of P-TEFb activity, and
the dissociation of CLP-1 from P-TEFb complex stimulates cardiac
hypertrophic phenotype [1,5,6]. The CTD of human RNA polymer-
ase II is composed of 52 repeats of a heptapeptide sequencechemical Societies. Published by E
as).Tyr-Ser-Pro-Thr-Ser-Pro-Ser. Cdk9 speciﬁcally phosphorylates
Ser2 of the CTD of RNA polymerase II [3], whereas Cdk7 speciﬁ-
cally phosphorylates Ser5 [7]. Both Cdk7 and Cdk9 are activated
during hypertrophic stimuli, but only Cdk9 is speciﬁcally acti-
vated during acute overload by aortic banding in the myocar-
dium [8]. Activation of Cdk9 causes cardiomyocyte enlargement
and defective mitochondrial function, via diminished peroxisome
proliferator-activated receptor gamma coactivator 1 (PGC-1)
transcription, and confers a predisposition to heart failure [9].
In our recent study using isolated mouse heart ischemia–
reperfusion model, we have demonstrated that downregulation
of CLP-1 in heterozygous CLP-1+/ mice affords cardioprotection
against ischemia–reperfusion injury [10], where the CLP-1
remains associated with P-TEFb complex in the CLP-1+/ mice
hearts, and results in a decrease in Cdk7 and Cdk9 activities,
and an enhanced level of PGC-1a and hypoxia-inducible factor1a
(HIF-1a). Our present study shows that CLP-1 downregulation-
mediated cardioprotection against cardiac ischemia–reperfusion
injury involved the elicitation of redox active proteins such as
redox effector factor-1 (Ref-1), nuclear factor erythroid 2-related
factor (Nrf2), NADPH oxidase 4 (NOX4) and thioredoxin super
family members.lsevier B.V. All rights reserved.
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2.1. Animals
All animals used in this study received humane care in compli-
ance with the regulations relating to animals and experiments
involving animals and adheres to principles stated in the Guide
for the Care and Use of Laboratory Animals, NIH Publication,
1996 edition, and all the protocols were approved by Institutional
Animal Care Committee.
2.2. Isolated working heart preparation and drug treatment
Wild-type CLP-1++ and heterozygous CLP-1+/ mice were anes-
thetized with sodium pentobarbital (80 mg/kg, i.p.) (Abbott Labo-
ratories, North Chicago, IL, USA), and intraperitonealy heparin
sodium (500 IU/kg, i.v.) (Elkins-Sinn Inc., Cherry Hill, NJ, USA)
was used as an anticoagulant. After the deep anesthesia was con-
formed, hearts were excised, the aorta was canulated, and the
hearts were perfused through the aorta in Langendorff mode at a
constant (100 cm of water) perfusion pressure at 37 C with the
KHB for a 5 min washout period as described previously. The per-
fusion medium consisted of a modiﬁed Krebs–Henseleit bicarbon-
ate buffer (millimolar concentration: sodium chloride 118,
potassium chloride 4.7, calcium chloride 1.7, sodium bicarbonate
25, potassium dihydrogenphosphate 0.36, magnesium sulfate 1.2
and glucose 10), and after its oxygenization pH was 7.4 at 37 C.
During the washout period left atria was canulated, and the Lange-
ndorff preparation was switched to the working mode for 10 min
with a left atrial ﬁlling pressure of 17 cm H2O, aortic afterload pres-
sure was set to 100 cm of water. At the end of 10 min, baseline car-
diac function like heart rate (HR, beats/min), aortic ﬂow (AF, ml/
min), coronary ﬂow (CF, ml/min), left ventricular developed pres-
sure (LVDP, mmHg) and ﬁrst derivative of developed pressure
(LVdp/dt, mmHg/s) were recorded. After that 30 min of global
ischemia was initiated by clamping the left atrial inﬂow and aortic
outﬂow lines at a point close to their origins. At the end of the
30 min of ischemia, reperfusion was initiated for 120 min by
unclamping the atrial inﬂow and aortic outﬂow lines. The ﬁrst
10 min reperfusion was in Langendorff mode to avoid the ventric-
ular ﬁbrillations, after the hearts were switched to anterograde
working mode.
2.3. Cardiac function assessment
Aortic pressure was measured using a Gould P23XL pressure
transducer (Gould Instrument Systems Inc., Valley View, OH,
USA) connected to a side arm of the aortic cannula. The signal
was ampliﬁed using a Gould 6600 series signal conditioner and
monitored on a CORDAT II real-time data acquisition and analysis
system (Triton Technologies, San Diego, CA, USA). Heart rate, LVDP
(deﬁned as the difference of the maximum systolic and diastolic
aortic pressures), and dp/dt were all derived or calculated from
the continuously obtained pressure signal. Aortic ﬂow was mea-
sured using a calibrated ﬂow-meter (Gilmont Instrument Inc., Bar-
rington, IL, USA) and coronary ﬂow was measured by timed
collection of the coronary efﬂuent dripping from the heart.
2.4. Cytosolic extract preparation
About 100 mg of left ventricular tissue was homogenized in
1 ml of buffer containing 25 mM Tris, 25 mM NaCl, 1 mM sodium
orthovanadate, 10 mM sodium ﬂuoride, 10 mM sodium pyro-
phosphate, 0.5 mM EDTA, 1 mM PMSF and protease inhibitors
cocktail (leupeptin, aprotinin, and pepstatin). Homogenates werecentrifuged at 3000 rpm for 10 min at 4 C, and the supernatant
was again centrifuged at 10 000 rpm for 20 min at 4 C. The
resultant supernatant was saved as cytosolic extract. Total pro-
tein concentration in the cytosolic extract was determined using
BCA Protein Assay Kit (Pierce, Rockford, IL).
2.5. Western blot analysis
Total cell lysate from mice heart tissue was separated in SDS–
PAGE and transferred to nitrocellulose ﬁlters. Filters were blocked
in 5% non-fat dry milk, and probed with a primary antibody
(1:1000 dilution) for overnight. Ref-1 primary antibody was ob-
tained from Cell Signaling Technology. Nrf2, heme oxygenase-1
and NOX4 primary antibodies were obtained from Santa Cruz Bio-
technology. Protein bands were identiﬁed with horseradish perox-
idase conjugated secondary antibody (1:2000 dilution) and
Western Blotting Luminol Reagent (Santa Cruz Biotechnology).
The resulting blots were digitized, subjected to densitometric scan-
ning using a standard NIH image program, and normalized against
loading control.
2.6. Immunoﬂuorescence staining
Heart tissue samples collected at the end of experiments were
ﬁxed in 4% buffered paraformaldehyde (pH 7.4), embedded in par-
afﬁn and sectioned. After deparafﬁnizing the sections the antigen
retrieval treatment was performed using 10 mM sodium citrate
containing 0.05% Tween 20 at 90–95 C for 30 min. After washing
with PBS, the slides were blocked with Powerblock (BioGenex,
San Ramon, CA) for 10 min. Slides were washed with PBS and incu-
bated with primary antibodies (1:25 dilution) in PBS containing 1%
BSA for 2 h. After washing, the slides were incubated with ﬂuores-
cein-conjugated secondary antibodies (anti-rabbit Alexa Fluor 488,
green; and anti-goat Alexa Fluor 594, red; both from Molecular
Probes and used at 1:1000 dilutions) in the dark for 45 min. For nu-
clear staining To-Pro 3 iodide (Molecular Probes; 1:1000 dilution)
was used for 45 min in the dark. The slides were washed and cov-
ered with mounting medium. Confocal microscopic images were
obtained using a Zeiss LSM 510 (Thornwood, NY) confocal laser
scanning microscope with 40  1.3 oil immersion objective by
simultaneous recording in the 488k, 560k, and/or 615k channels
as appropriate.
2.7. Semi-quantitative RT-PCR
Total RNA was extracted from liver tissue, using Trizol reagent
(Invitrogen, CA, USA). Three micrograms of total RNA was re-
verse-transcribed, using a SuperScript-II First-Strand Synthesis
System (Invitrogen) with oligo dT12-18, according to the manufac-
turer’s protocol. The cDNA was ampliﬁed by PCR, using Platinum
Taq-DNA polymerase (Clontech, CA, USA) following a standard
semi-quantitative RT-PCR technique in which the ampliﬁed prod-
ucts were not saturated at the number of cycles performed. The
primers used for the ampliﬁcation are enlisted in Table 1. The
PCR products were visualized by electrophoresis in 1% agarose
gel (Bio-Rad, CA, USA) with ethidium bromide (0.5 lg/ml; Sigma,
MO, USA).
2.8. Statistical analysis
All values are expressed as the means ± standard error of mean
(S.E.M.). Student’s t-test or one way analysis of variance test fol-
lowed by Bonferoni’s correction was ﬁrst carried out to test for
any differences between the mean values of all groups. The results
were considered signiﬁcant if P < 0.05.
Table 1
Sequences of primer used in this study.
Name of
genes
Forward primer (50–30) Reverse primer (50–30)
Trx-1 CACGAGGATTTCCATCTGGT CCACACCACGTAGCAGAGAA
Trx-2 CATTTCCTCTCCTGCCTCTG TGTTCACAGCTCCTCCTCCT
Grx-1 CCAAGCAGCTGTGTGTTGAT CTCACCGGAGACCAGAGAAG
Grx-2 GTTTCAAGATGCGCTTCACA TGGTATGGCGACTATCCACA
TrxR-1 AGCTGCCAACAATGAATGGC TTAACCTCAGCAGCCAGACT
TrxR-2 GCAGAGCTTTGATCTCTTGG AGAAGCATGATCCTCCCAAG
Prx-II CGGAGATCATCGCTTTTAGC TTGACTGTGATCTGGCGAAG
Prx-IV CAAAGCCAAGATCTCCAAGC TGAACCAAACGCAGTGTCTC
CLP-1 GAGAACTCTACTAAGCCATGGC TTCAGTCTAGTCGCCGAACTTG
a-Actin CGATATCCGCAAAGACCTGT GCTGGAAGGTGGACAGAGAG
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3.1. CLP-1 heterozygous mice hearts are resistant against ischemia–
reperfusion injury
Isolated hearts from CLP-1+/+ and CLP-1+/ mice were subjected
to ischemia/reperfusion and the functional parameters were mea-
sured as described in Section 2. After reperfusion, the cardiac func-
tional parameters such as aortic ﬂow, left ventricular developed
pressure, and the ﬁrst derivative of developed pressure (dP/dt
max) were signiﬁcantly improved in the CLP-1+/ hearts than those
of wild-type CLP-1+/+ mice (Fig. 1). However, no signiﬁcant differ-
ence was observed in heart rate and coronary ﬂow between the
groups (Fig. 1).WT-IR
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Fig. 1. Isolated hearts obtained from control and CLP-1+/ animals was subjected to 30 m
prior to ischemia and during 30, 60 and 120 min of reperfusion. Results are expressed as m
pressure, LVdp/dt, maximum ﬁrst derivative of LVDP. *P < 0.05. vs. Control.3.2. Redox activation in CLP-1+/ mice after ischemia–reperfusion
Our previous study demonstrated that the level of PGC-1a and
HIF-1a were elevated after ischemia reperfusion injury in CLP-1+/
 mice hearts compared to wild-type hearts [10]. Since PGC-1a is
known to regulate the metabolism of reactive oxygen species
[11], and HIF-1a play an important role in oxygen sensing
[12,13], we evaluated the role of redox signaling in the CLP-1
downregulation-mediated cardioprotection. Western-immunoblot
analysis and its quantiﬁcation showed that the level of expression
of redox signaling molecules Ref-1, Nrf2, NOX4 were increased in
CLP-1+/ mice hearts compared to wild-type hearts after ischemia
reperfusion (Fig. 2A and B). The enhanced expression of Ref-1,
Nrf2 and NOX4 (Fig. 3) were also conﬁrmed by the confocal
immunoﬂuorescence analysis. However, the expression of heme
oxygenase-1 did not differ signiﬁcantly between groups (Fig. 2A
and B).
3.3. Role of thioredoxin super family in CLP-1+/ mediated
cardioprotection
RT-PCR analysis indicates that the level of CLP-1 mRNA in
baseline and after ischemia reperfusionwas decreased in CLP-1 het-
erozygous mice hearts compared to the wild-type hearts. The level
of CLP-1 mRNA did not differ after ischemia–reperfusion injury in
wild-typemice hearts. ThemRNA levels of thioredoxin super family
members including thioredoxin-1 (Trx-1), thioredoxin-2 (Trx-2),
glutaredoxin-1 (Grx-1), and glutaredoxin-2 (Grx-2) were decreased
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in ischemia followed by 120 min of reperfusion. Cardiac functions were measured
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Fig. 2. Total tissue lysates were obtained from both wild-type and CLP-1+/ animal hearts before and after subjecting them to ischemia–reperfusion injury. Western-blotting
analysis (A) and its quantiﬁcation (B) were carried to study the expression of redox-regulated proteins, such as Ref-1, Nrf2, heme oxygenase-1 and NAPDH oxidase 4. *P < 0.05.
vs. WT-BL, WT-I/R and KO-BL. WT, wild-type; BL, base line; KO, CLP-1+/; and I/R, ischemia–reperfusion.
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rate was higher in CLP-1+/ mice after ischemia–reperfusion than
its steady state level. However, the mRNA decay of Trx-1, Trx-2,
Grx-1 and Grx-2 did not differ between the wild-type mice groups
(Fig. 4). In contrast, the level of thioredoxin reductase-1 (TrxR-1)
mRNA was dramatically increased after ischemia–reperfusion than
its baseline level in CLP-1+/ heterozygous mice hearts (Fig. 4). At
the same time, the mRNA level of TrxR-1 was decreased after ische-
mia–reperfusion than its baseline level in thewild-typemice hearts
(Fig. 4). However, themRNA level thioredoxin reductase-2 (TrxR-2),
peroxiredoxin-II (Prx-II) and peroxiredoxin-IV (Prx-IV) did not vary
among the groups (Fig. 4).
4. Discussion
Reactive oxygen species such as superoxide anions, hydrogen
peroxide, hydroxyl radicals are normally produced in cells during
oxidative phosphorylation and play a role in redox control of phys-
iologic signaling pathways [14]. Excessive ROS can induce oxida-
tive damages to DNA, lipids, proteins, and other macromolecules
[14]. The intracellular redox state is characterized by the balancebetween the oxidant production and the antioxidant capacity of
the cell. A variety of cellular antioxidant enzymes (superoxide dis-
mutase, catalase, and glutathione peroxidase) and nonenzymatic
antioxidant molecules (vitamin E, vitamin C, b-carotene, ubiqui-
none, lipoic acid, and urate) play an important role in maintaining
the cellular redox status [15]. The thioredoxin system (thioredoxin,
thioredoxin reductase), glutaredoxin system (glutaredoxin, gluta-
thione and glutaredoxin reductase) and NADPH, form an additional
integrated antioxidant defense system, which operates as a power-
ful protein–disulﬁde oxidoreductase [16]. At lower concentrations,
ROS serve as second messengers that transmit biological informa-
tion, which is known as redox signaling that involves the activation
of many signal-transduction protein kinases and transcription fac-
tors, the stimulation of DNA synthesis, and expression of growth-
related genes [17].
In our recent study using isolated mouse heart ischemia–
reperfusion model, we have demonstrated that downregulation
of CLP-1 in heterozygous CLP-1+/ mice affords cardioprotection
against ischemia–reperfusion injury [10], where the CLP-1 is
found to remain associated with P-TEFb complex in the CLP-1+/
mice hearts, leading to a decrease in Cdk7 and Cdk9 activities,
Fig. 3. Representative confocal immunoﬂuorescence microscopic images of the formaldehyde ﬁxed parafﬁn embedded heart tissue sections obtained from wild-type and
CLP-1+/ mice stained with Ref-1 antibody followed by AlexaFluor 488 (green) conjugated secondary antibody or stained with Nrf2 antibody followed by AlexaFluor 488
(green) conjugated secondary antibody or stained with NOX-4 antibody followed by AlexaFluor 594 (red) conjugated secondary antibody. Nuclear staining was performed
with Topro-3-iodide (blue). The nuclear colocalization of Ref-1 and Nrf2 in the CLP-1+/ mice hearts are shown in white (indicated by arrows).
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PGC-1a, HIF-1a and pyruvate dehydrogenase kinase-1 (PDK-1)
[10]. Our results are in consistent with those reported earlier,
where Cdk9 activity was shown to suppress many genes for mito-
chondrial proteins including master regulators of mitochondrial
function PGC-1 [8,9]. Chronic activation of Cdk9 causes not only
cardiomyocyte enlargement but also defective mitochondrial
function, via diminished PGC-1 transcription, and a resulting sus-
ceptibility to apoptotic cardiomyopathy [9]. Since HIF-1a expres-
sion during hypoxic conditions is known to induce PDK-1, which
facilitates cell adaptation to low oxygen pressure by repressing
mitochondrial function and by reactive oxygen species production[18,19]. PDK-1 overexpression in hypoxic HIF-1a null cells in-
creases ATP levels, attenuates hypoxic ROS generation, and res-
cues them from hypoxia-induced apoptosis [20]. HIF-1
stimulates glycolysis, and actively represses mitochondrial func-
tion and oxygen consumption by inducing PDK-1 [18,19]. PDK-1
phosphorylates and inhibits pyruvate dehydrogenase from using
pyruvate to fuel the mitochondrial TCA cycle [18,19]. This causes
a drop in mitochondrial oxygen consumption and results in a rel-
ative increase in intracellular oxygen tension [18,19]. Thus, the
reduced level of reactive oxygen species production is maintained
in CLP-1+/ mice via enhanced level PDK-1, which reduces the
oxidative phosphorylation, and increases the glycolysis. In the
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Fig. 4. RT-PCR analysis of thioredoxin super family members in CLP-1+/ mediated
cardioprotection. Total RNA was isolated from the isolated heart tissue sections and
3 lg of total RNA was reverse-transcribed using First-Strand Superscript-II cDNA
synthesis kit (Invitrogen). PCR was performed using speciﬁc primers and conditions
using clontech Platinum Taq-DNA polymerase, followed by gel electrophoresis.
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through ischemia–reperfusion injury in the CLP-1+/ mouse hearts
involved in the generation of redox signaling as evidenced by the
increased production of NOX4, Nrf2, Ref-1 in CLP-1+/ mouse
hearts when compared to wild-type mouse hearts. These results
are in consistent with the previous report that ROS generated
via UV radiation or H2O2 treatment remarkably induce the levels
of Ref-1, which corresponds with the increase in endonuclease
and redox activities of Ref-1 [21]. Ref-1 facilitates the DNA bind-
ing and activation of several transcription factors via reduction of
a cysteine residue [22]. ROS can also affect the functions of Ref-1.
For example, oxidative stress severely affects both DNA repair and
the redox regulation activities of Ref-1 [23]. Our results suggest
that oxidative stress induced via ischemia–reperfusion injury
could have signiﬁcantly affected the redox regulation of Ref-1. It
is tempting to speculate that the redox signaling mediated via
Ref-1 and Nrf2 in CLP-1+/ mouse hearts could have attenuated
the ischemia–reperfusion-induced oxidative stress leading to car-
dioprotection in CLP-1+/ mice. As shown in previous studies [24],
our results suggest that the enhanced expression of NOX-4 could
play an important role in the redox signaling in CLP-1+/ mouse
hearts. Nrf2 is a member of basic leucine zipper transcription fac-
tors and is known to induce many genes involved in the stress-
responsive and cytoprotective proteins such as glutathione perox-
idase, thioredoxin, catalase, and superoxide dismutase [25]. In the
current study, we found that the mRNA level of Trx-1, Trx-2, Grx-
1 and Grx-2 are reduced. Our results are in consistent with the
results of other studies, where it has been demonstrated that
the mRNAs that code for proteins produced in response to inter-
nal or external stimuli will have short half-lives [26]. In other
words, the reduced level of Trx-1, Trx-2, Grx-1 and Grx-2 mRNAs
indicate that they are actively being used to attenuate the ROS
produced in association with ischemia–reperfusion injury inCLP-1+/ mice hearts. The mRNA level of TrxR-1, which is re-
quired to convert back the oxidized Trx-1 to reduced Trx-1, was
increased.
Environmental stresses such as heat shock, and UV radiation
and myocardial ischemia–reperfusion injury are known to induce
oxidative stress. Controlled amount of oxidative stress induces
the expression of intracellular antioxidants leading to enhanced
myocardial tolerance to ischemia [27], and redox signaling in
the ischemic adaptation induces stress-inducible proteins
through the activation of transcription factors [28]. Thioredoxin
and glutaredoxin play an essential role in maintaining the intra-
cellular environment in a reduced state via redox signaling in
the ischemic myocardium, where redox signaling converts cellu-
lar death signal into survival signal [28]. In conclusion, our re-
sults suggest that the downregulation of CLP-1 in CLP-1+/
mice leads to the potentiation of redox signaling thereby gener-
ating their molecular targets after ischemia reperfusion injury. It
would further suggest that drugs designed to down regulate CLP-
1 could confer cardioprotection through the potentiation of re-
dox cycling.Acknowledgements
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